S. Sugarman

发表

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Alison Stopeck, Sarat Chandarlapaty, Neal Rosen, 2011, Clinical Cancer Research.

Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.

A. Grollman, S. Shibutani, N. Suzuki, 2000, Carcinogenesis.

Liposomes in the treatment of malignancy: a clinical perspective.

R. Perez-soler, S. Sugarman, 1992, Critical reviews in oncology/hematology.

Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies

R. Perez-soler, Y. Zou, K. Wasan, 1996, Cancer Chemotherapy and Pharmacology.

Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.

C. Hudis, A. Vickers, G. Deng, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of adjuvant therapy in surgically resected colorectal carcinoma.

F. Sinicrope, S. Sugarman, 1995, Gastroenterology.

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.

J. Ajani, R. Pazdur, J. Abbruzzese, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

E. Winer, C. Hudis, L. Norton, 2011, Clinical Cancer Research.

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

D. Lake, C. Hudis, L. Norton, 2009, Breast Cancer Research and Treatment.

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.

J. Murray, N. Onetto, D. Healey, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I T rial o f t he A nti-Lewis Y D rug I mmunoconjugate BR96-Doxorubicin i n P atients W ith L ewis Y -Expressing Epithelial T umors

J. Murray, N. Onetto, Dennie V. Jones, 2000 .

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.

C. Hudis, L. Norton, J. Baselga, 2017, The oncologist.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

D. Lake, C. Hudis, L. Norton, 2016, Clinical breast cancer.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

S. Chandarlapaty, D. Lake, C. Hudis, 2014, Clinical breast cancer.

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

H. Linden, C. Hudis, N. Rosen, 2008 .

Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen.

A. Grollman, S. Shibutani, N. Suzuki, 1999, Chemical research in toxicology.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

S. Chandarlapaty, C. Hudis, L. Norton, 2016, Breast Cancer Research and Treatment.

Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.

M. Viola, H. Malhotra, R. Caruso, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.

J. Ajani, B. Levin, R. Pazdur, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

K. Hess, L. Zwelling, J. Abbruzzese, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast

C. Rudin, D. Gomez, S. Powell, 2021, International Journal of Radiation Oncology*Biology*Physics.

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

M. Berger, S. Chandarlapaty, D. Lake, 2015 .

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

M. Berger, S. Chandarlapaty, D. Lake, 2015 .

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

K. Gelmon, A. Tolcher, C. Isaacs, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

E. Winer, C. Hudis, L. Norton, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer

P. Cordeiro, J. Laragh, D. Lake, 2011, Clinical Cancer Research.

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.

D. Lake, C. Hudis, L. Norton, 2010, Clinical breast cancer.

Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.

S. Lippman, D. Moore, R. Pazdur, 1995, American journal of clinical oncology.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

D. Lake, C. Hudis, L. Norton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.

D. Lake, C. Hudis, L. Norton, 2008, Clinical breast cancer.

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

H. Cohen, C. Isaacs, J. Clapp, 2017, Breast Cancer Research and Treatment.

P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).

S. Chandarlapaty, D. Lake, M. Moynahan, 2011 .

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.

E. Winer, C. Hudis, L. Norton, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I C hemotherapy S tudy o f B iochemical M odulation o f Folinic A cid a nd F luorouracil b y G emcitabine i n P atients With S olid T umor M alignancies

M. Viola, H. Malhotra, R. Caruso, 2000 .

Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.

C. Hudis, A. Vickers, G. Deng, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.

C. Hudis, L. Norton, M. Moasser, 2009 .

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer

P. Cordeiro, J. Laragh, D. Lake, 2011, Clinical Cancer Research.

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

J. Reis-Filho, N. Riaz, D. Higginson, 2023, The Lancet.